A Field Guide to Incretin-Class Research Peptides

The short version

Peptides Long Island is a field guide, not a storefront. It exists to read three peptides that keep surfacing in metabolic-research conversations — MOTS-c, retatrutide, and semaglutide — against what has actually been published about them, in plain language, with a citation attached to every claim that needs one.

The three do not share one mechanism. Semaglutide and retatrutide are incretin mimetics: synthetic peptides that copy gut hormones (GLP-1, GIP, and, for retatrutide, glucagon) released after eating, which regulate blood sugar and appetite. MOTS-c is something else entirely — a mitochondrial-derived peptide, made from a short stretch of DNA hidden inside the mitochondrion (the small structure inside cells that generates energy), that appears to act through a cellular energy-sensor enzyme called AMPK.

The evidence behind each is wildly uneven, and this guide says so plainly: semaglutide has years of large human trials, retatrutide has two years of Phase 2 data, and MOTS-c has essentially none in humans. This site sells nothing, recommends no dose, and gives no medical advice.

What are research peptides?

Peptides are short chains of amino acids — smaller cousins of the proteins that do most of the structural and signaling work in the body. The three compounds on this guide fall into two families. Semaglutide and retatrutide are engineered analogues of natural gut hormones, chemically modified with fatty-acid side chains that bind serum albumin and slow their breakdown, extending a natural hormone's minutes-long half-life out to about a week — the structural basis for once-weekly dosing in both.

MOTS-c belongs to a newer, stranger family: peptides encoded not in nuclear DNA but inside the mitochondrial genome itself, discovered only in the last decade and still being mapped mechanistically. Semaglutide is an FDA-approved prescription medicine. Retatrutide is an investigational drug in Phase 3 trials, not yet approved anywhere. MOTS-c has no regulatory pathway underway at all — it is sold strictly as a laboratory research chemical, with no human clinical trial program on record. This guide reports each status exactly as it stands and never blurs the three together.

How these three fit into this guide

Semaglutide is the benchmark: the first incretin mimetic to demonstrate large-scale, durable weight loss alongside cardiovascular and kidney benefit in landmark trials with thousands of participants ^[12][13][14]. Retatrutide pushes the incretin idea further by adding a third receptor arm — glucagon — on top of GIP and GLP-1, and posted the largest Phase 2 weight-loss figures reported for any agent in the class, roughly -24% at 48 weeks ^[9], though it remains investigational with no Phase 3 results published. MOTS-c sits outside that ladder altogether: it is included here because its proposed metabolic role — improving glucose handling and insulin sensitivity in skeletal muscle through AMPK — puts it squarely in the same research conversation, even though its evidence base is animal and cell work almost without exception ^[1][3][4].

Reading the three together is instructive precisely because they occupy different rungs of the same evidentiary ladder: one approved medicine, one investigational Phase 2 compound, and one preclinical research peptide. Use the comparison page for the side-by-side.

A note on how this guide reads the evidence

Each peptide page on this site cites its sources by number against a single shared references list. Where a finding comes from a large randomized trial, this guide says so and gives the population and duration studied. Where it comes from a mouse study, a cell-free assay, or a single observational cohort, this guide says that too — the trial programs behind semaglutide are a different category of evidence than the mouse-and-cell-model literature behind MOTS-c, and treating them as equivalent would be dishonest. Community-reported effects appear only where the underlying corpus documents them, and always under an explicit anecdotal label — this guide does not invent user experiences for a compound that has none on record. The aim is a disciplined map of what is actually known, compound by compound, so a reader can calibrate confidence rather than absorb a flattened conclusion.